SWOOSH RECOVERY VS. LIQUIDITY SPLASH

The exit from the lockdowns is proceeding cautiously. If anything the number of new cases globally has picked up over the past week, flirting with 100k on 15 May, the highest since 16 April (see our latest Facts and Figures, including new modelling). Scientists keep warning about the risk of relaxing social distancing too quickly. In the meantime the global economy struggles – we slightly cut our 2020 global growth forecast from -3.5% to -4%.

Highlights:

  • While the exit from the lockdown is proceeding cautiously, Covid-19 appears tenacious; the number of new cases globally has slightly picked up over the past week.
  • We go back to history and look at the shape of recessions and recoveries. From peak to trough, the US GDP is set to lose at least 13%, vs. “just” 4% through the 2008-09 Great Financial Crisis (Euro area -14% vs -6%).
  • The shape of the recovery matters both socially and financially. The ‘swoosh’ recovery does not bode particularly well for cyclicals assets.
  • Arguably, unprecedented central bank actions will support elevated equity multiples. The balance sheet of G4 central banks will grow as much this year as between 2008 and 2016.
  • The liquidity splash and limited appetite for risk (typical in post-traumatic periods) will support assets offering some yield but a contained risk profile, such as Investment Grade corporate bonds, non-cyclical sectors, growth stocks and residential property..

Download the full publication below

Swoosh Recovery vs. Liquidity Splash

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
Q3 EARNINGS SEASON STARTS WELL. EXPECT STABILIZATION IN REVISIONS MOMENTUM BUT RECOVERY WILL CONTINUE
The Q3 reporting season has just started. For the US, expectations are for a yearly earnings growth of -21% after -31% in Q2. As for sectors, worse growth rates in the US are expected for energy, industrials and discretionary while pharma, utilities, IT and staples should rank better than the index.